论文部分内容阅读
1 材料与方法 1.1 病例选择 治疗组和对照组均为我院1995年～1996年5月住院病人,共102例,符合1995年5月北京第五次全国传染病寄生虫病学术会议讨论修订的病毒性肝炎防治方案(试行)中的急性黄疸型肝炎诊断标准,随机分为两组,其中治疗组55例,对照组47例。治疗组男28例,女27例,年龄31.07±7.91岁,起病天数7.67±3.13天,ALT1411.52±55.710U/L,TB 75.75±33.52μmol/L。对照组男30例,女17例,年龄33.79±8.55岁,发病天数7.71±3.11天,ALT1290.63±626.97U/L,TB89.60±37.96μmol/L。治疗组全为急性黄疸型肝炎,其中甲型48例,乙型7例。对照组45例为急性黄疸型肝炎,2例为急性无黄疸型肝炎,甲型41例,乙型6例。两组病例在性别、年龄、起病天数、病情和ALT、TB方面无统计学差异(P>0.05)。 1.2 治疗方法 1.2.1 治疗组 使用一般护肝药物及维生素类治疗的同时加用上海新亚药业公司生产的1,6二磷酸果糖(FDP)10g,用注射用水100ml溶解后,在15
1 Materials and Methods 1.1 Case Selection The treatment group and control group were hospitalized in our hospital from 1995 to May 1996, a total of 102 cases, in line with the Fifth National Conference on Infectious Diseases parasitic disease in Beijing in May 1995 to discuss the revised The diagnostic criteria of acute jaundice hepatitis in the prevention and treatment program of viral hepatitis (trial) were randomly divided into two groups, 55 in the treatment group and 47 in the control group. Treatment group, 28 males and 27 females, aged 31.07 ± 7.91 years, onset days 7.67 ± 3.13 days, ALT1411.52 ± 55.710U / L, TB75.75 ± 33.52μmol / L. The control group, 30 males and 17 females, aged 33.79 ± 8.55 years, onset days 7.71 ± 3.11 days, ALT1290.63 ± 626.97U / L, TB89.60 ± 37.96μmol / L. The treatment group were all acute jaundice hepatitis, including 48 cases of type A and 7 cases of type B. Control group, 45 cases of acute jaundice hepatitis, 2 cases of acute jaundice hepatitis, 41 cases of type A, 6 cases of type B. There was no significant difference between the two groups in gender, age, days of onset, disease and ALT, TB (P> 0.05). 1.2 treatment 1.2.1 treatment group using general liver drugs and vitamins at the same time with the Shanghai New Asia Pharmaceutical Company production of fructose 1,6 diphosphate (FDP) 10g, 100ml with water for injection dissolved in 15